Outgoing CEO Kevin Sayer expects expanding coverage of Dexcom’s glucose sensors for people with Type 2 diabetes and ...

Innovations are expanding the number of people who can benefit from continuous glucose monitoring and a recent move by ...

Medical device company DexCom (NASDAQ:DXCM) in Q2 CY2025, with sales up 15.2% year on year to $1.16 billion. The company ...

DexCom, Inc. DXCM reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, which beat the Zacks Consensus ...

The recall affects Dexcom G6, G7, ONE, and ONE+ continuous glucose monitor receivers but not the smartphone apps or insulin ...

SAN DIEGO - Dexcom reported revenue growth of 15% year-over-year to $1.157 billion for the second quarter of 2025.

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

Dexcom's growth in sensors and U.S. expansion is solid, but slowing revenue growth and high valuation limit upside. Click ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections of the company’s facilities in San Diego ...

With an overall MARD of 8.0%, 3 Dexcom G7 15 Day builds on the performance of Dexcom CGM, which is clinically proven to lower A1C, reduce hyper- and hypoglycemia and increase time in range. 4-8 ...

DexCom, Inc. (DXCM - Free Report) reported second-quarter 2025 adjusted earnings per share (EPS) of 48 cents, which beat the ...